ストックスクリーナーアプリを入手
4.08
7.37%
0.28
アフターアワーズ：
4.01
-0.07
-1.72%
Bluebird Bio Inc (BLUE) 最新ニュース
Turbulence at the FDA & bluebird Bio’s sale - STAT
bluebird bio stock slides for second day on buyout news - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate bluebird bio, Inc. (BLUE) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Drug and Gene Delivery Devices Market Growth in Future Scope - openPR
bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024BLUE - ACCESS Newswire
Bluebird bio chief business officer Joseph Vittiglio sells $1,759 in stock - MSN
Levi & Korsinsky Reminds bluebird bio Investors of the Ongoing Investigation into Potential Violations of Securities LawsBLUE - ACCESS Newswire
BLUE DEADLINE ALERT: Bernstein Liebhard LLP Reminds bluebird bio, Inc. Investors of Upcoming Deadline - ACCESS Newswire
Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class ActionBLUE - ACCESS Newswire
Carlyle and SK Capital’s Acquisition of bluebird bio - Global Legal Chronicle
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc.BLUE - Business Wire
Bluebird bio stock slides for second day on buyout news (NASDAQ:BLUE) - Seeking Alpha
JPMorgan Upgrades bluebird bio to Neutral From Underweight -February 24, 2025 at 07:36 am EST - Marketscreener.com
JP Morgan Upgrades bluebird bio (BLUE) - Nasdaq
Troubled gene therapy player bluebird sold for a song - pharmaphorum
Amneal pharma, Aramark, Bluebird Bio - TradingView
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital - BioSpace
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital - MSN
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow - Genetic Engineering & Biotechnology News
bluebird bio announces take-private deal with Carlyle and SK Capital - MSN
IMMINENT BLUE DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds bluebird bio, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
bluebird bio plunges after take-private deal with Carlyle and SK Capital - MSN
Private equity firms rescue bluebird bio out of its misery - The Pharma Letter
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - MSN
Gene therapy maker bluebird to go private in discounted deal amid cash crunch - MSN
Cash-Strapped Gene Therapy Firm Bluebird Bio Agrees to Acquisition by Private Equity - MedCity News
Carlyle and SK Capital to acquire bluebird bio By Investing.com - Investing.com Nigeria
Bluebird bio stock plunges to 52-week low of $4.89 amid challenges - Investing.com Nigeria
Latham & Watkins Advises bluebird bio in Acquisition by Carlyle and SK Capital - Latham & Watkins LLP
Investment firms Carlyle and SK Capital to acquire gene therapy developer bluebird bio - BioProcess Insider
BofA moves to No Rating on Bluebird Bio after deal announcement - TipRanks
Dow Tumbles Over 700 Points; US Services PMI Falls In February - Benzinga
bluebird bio Sale to Carlyle and SK Capital Partners - Leerink Partners
Cautious Hold Rating for Bluebird Bio Amid Strategic Shift and Uncertain Sales Milestones - TipRanks
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch -February 21, 2025 at 08:14 am EST - Marketscreener.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc.BLUE - PR Newswire
Struggling bluebird bio to go private for less than $30m - Pharmaceutical Technology
Cheap-cheap? Bluebird dodges bankruptcy with $30M buyout - BioWorld Online
Bluebird bio Agrees to be Acquired by Carlyle Group, SK Capital Partners; Shares Fall Sharply - Marketscreener.com
Bluebird bio to sell to investment funds after struggling to make money from gene therapies - Endpoints News
SK Capital Partners, LP and The Carlyle Group Inc. (NasdaqGS:CG) entered into an agreemet to acquire bluebird bio, Inc. - Marketscreener.com
Cash-strapped bluebird bio to be sold for less than $30M upfront - FirstWord Pharma
Once valued at $10B, bluebird bio sold to private equity firms for $29M - FiercePharma
Bluebird, at risk of default, agrees to take-private deal - BioPharma Dive
Once a darling of biotech, bluebird sells for less than $30M upfront - The Business Journals
Carlyle and SK Capital take bluebird bio private in $477m deal - Private Equity Insights
Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch - KFGO
An awkward moment for Pfizer’s Bourla in Washington - STAT
Bluebird, Facing Cash Crunch, To Go Private In Deal Valued at $30M - BioSpace
Bluebird Bio downgraded to Neutral from Outperform at Baird - TipRanks
Bluebird Bio Announces Definitive Agreement To Be Acquired By Carlyle And SK Capital - Marketscreener.com
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders - Business Wire
Carlyle and SK Capital to acquire bluebird bio - Investing.com
Bluebird Bio To Be Taken Private By Carlyle And SK Capital Partners - Nasdaq
Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million - STAT
bluebird bio stock falls on take-private deal (BLUE:NASDAQ) - Seeking Alpha
0.22%
0.81%
大文字化:
|
ボリューム (24 時間):